Tag Archives: FDA Approval

Market Access Programs for Gene Therapies Increasing

Payers are planning for an increasing number of gene therapies being approved by developing new coverage programs

Hepatitis C and Specialty Pharmacy Market

Express Scripts Plans a Specialty Drug Price War over new hepatitis C treatments reports a recent Bloomberg News story. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill. Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so employers and health plan payers are […]